Site search

Clear filter
2901 results for '' found
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gu
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gu
/
Double-Blind Randomised Investigation of Bazedoxifene and conjugated estrogen for Depression in Menopausal Women (ACTRN12620001015932)
Double-Blind Randomised Investigation of Bazedoxifene and conjugated estrogen for Depression in Menopausal Women (ACTRN12620001015932)
/
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
/
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
/
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
/
A multi-centre, open-label innovation study in pancreatic cancer utilising NanoknifeĀ®  System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
A multi-centre, open-label innovation study in pancreatic cancer utilising NanoknifeĀ® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
/
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardio
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardio
/
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (N
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (N
/